Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

NCT00330161 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: vorinostat
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)